IL312650A - CDK4 inhibitor for cancer treatment - Google Patents

CDK4 inhibitor for cancer treatment

Info

Publication number
IL312650A
IL312650A IL312650A IL31265024A IL312650A IL 312650 A IL312650 A IL 312650A IL 312650 A IL312650 A IL 312650A IL 31265024 A IL31265024 A IL 31265024A IL 312650 A IL312650 A IL 312650A
Authority
IL
Israel
Prior art keywords
cancer
treatment
cdk4 inhibitor
cdk4
inhibitor
Prior art date
Application number
IL312650A
Other languages
English (en)
Hebrew (he)
Inventor
Tun Tun Lin
Jing Yang
Original Assignee
Pfizer
Tun Tun Lin
Jing Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Tun Tun Lin, Jing Yang filed Critical Pfizer
Publication of IL312650A publication Critical patent/IL312650A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL312650A 2021-12-02 2022-11-29 CDK4 inhibitor for cancer treatment IL312650A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US202263383969P 2022-11-16 2022-11-16
PCT/IB2022/061525 WO2023100070A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL312650A true IL312650A (en) 2024-07-01

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312650A IL312650A (en) 2021-12-02 2022-11-29 CDK4 inhibitor for cancer treatment

Country Status (9)

Country Link
US (1) US20250041298A1 (https=)
EP (1) EP4440576A1 (https=)
JP (1) JP2024542633A (https=)
KR (1) KR20240112931A (https=)
AU (1) AU2022400308B2 (https=)
CA (1) CA3240993A1 (https=)
IL (1) IL312650A (https=)
MX (1) MX2024006678A (https=)
WO (1) WO2023100070A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828822B (zh) * 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
FI4181920T3 (fi) * 2020-07-15 2025-11-20 Pfizer Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon
AU2021325426A1 (en) * 2020-08-13 2023-03-09 Astellas Pharma Inc. Combination therapy
AU2021345531B2 (en) * 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法

Also Published As

Publication number Publication date
US20250041298A1 (en) 2025-02-06
MX2024006678A (es) 2024-06-19
CA3240993A1 (en) 2023-06-08
EP4440576A1 (en) 2024-10-09
JP2024542633A (ja) 2024-11-15
AU2022400308A1 (en) 2024-05-16
AU2022400308B2 (en) 2026-02-12
TW202329970A (zh) 2023-08-01
KR20240112931A (ko) 2024-07-19
WO2023100070A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
IL308195A (en) RAS inhibitors for cancer treatment
IL288522A (en) Inhibitor of egfr for cancer treatment
EP3781564A4 (en) Compounds for the treatment of cancer
IL312650A (en) CDK4 inhibitor for cancer treatment
EP4010081A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
IL316829A (en) Menin-MLL inhibitors for cancer treatment
CA3255651A1 (en) Multispecific agents for treatment of cancer
IL304595A (en) Bicyclic tetrahydrozepine derivatives for cancer treatment
IL312171A (en) Innovative use of the quinazolinone compound for cancer treatment
IL307465A (en) Combined therapies for cancer treatment
LT3924340T (lt) Indazolil-izoksazolo dariniai, skirti ligų, tokių kaip vėžys, gydymui
IL289201A (en) Compounds for the treatment of cancer
IL305780A (en) Cancer treatment methods
CA3263923A1 (en) PRMT5 inhibitors that cooperate with MTA for use in cancer treatment
AU2022231043A1 (en) Chaperonin-containing tcp-1 inhibitors for the treatment of cancer
HK40108604A (en) Ras inhibitors for the treatment of cancer
HK40090718A (en) Atr inhibitors for the treatment of cancer
HK40074624A (en) Inhibition of sirp-gamma for cancer treatment
HK40114414A (en) Dr5-targeting multabodies for the treatment of cancer
CA3303484A1 (en) Bet inhibitors for the treatment of cancer
HK40093971A (en) Smarca4 inhibition for the treatment of cancer
HK40068194A (en) Fgfr inhibitors for the treatment of cancer
IL308088A (en) Mestitinib for the treatment of castrate-resistant prostate cancer
CA3273527A1 (en) Metap2 inhibitors for the treatment of prostate cancer
EP4452946A4 (en) CONNECTIONS FOR THE TREATMENT OF CANCER